Stocktoria
Sonoma Pharmaceuticals, Inc. SNOA
Sonoma Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2017 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.5M | $14.3M | $12.7M | $13.3M | $12.6M | $18.6M | $17.9M | $19.0M | $16.7M | $12.8M |
| Gross profit | $7.4M | $5.5M | $4.7M | $4.5M | $4.0M | $6.6M | $8.1M | $8.9M | $7.3M | $5.7M |
| R&D expense | $2.3M | $1.8M | $1.9M | $207,000 | $125,000 | $555,000 | $1.3M | $1.5M | $1.6M | $1.6M |
| SG&A expense | $7.6M | $7.4M | $7.6M | $8.8M | $9.8M | $9.5M | $14.2M | $18.6M | $19.9M | $17.1M |
| Operating income | -$2.5M | -$3.7M | -$4.7M | -$4.6M | -$5.9M | -$3.4M | -$7.4M | -$11.3M | -$14.2M | -$13.0M |
| Interest expense | — | — | — | — | — | $12,000 | $16,000 | $33,000 | $40,000 | $3,000 |
| Income tax | -$244,000 | $550,000 | -$196,000 | -$33,000 | -$332,000 | $713,000 | $29,000 | $458,000 | $50,000 | -$4.3M |
| Net income | -$3.2M | -$3.5M | -$4.8M | -$5.2M | -$5.1M | -$4.0M | -$3.3M | -$11.8M | -$14.3M | $9.3M |
| EPS (diluted) | $-1.89 | $-2.79 | $-10.63 | $-1.52 | $-1.92 | — | — | — | — | — |
| Operating cash flow | -$3.9M | -$88,000 | -$2.4M | -$6.2M | -$4.2M | -$3.4M | -$4.6M | -$11.7M | -$12.4M | -$8.2M |
| Free cash flow | -$4.1M | -$168,000 | -$2.4M | -$6.4M | -$4.4M | -$3.6M | -$4.8M | -$11.8M | -$12.6M | -$8.6M |
| Cash & equivalents | $2.4M | $5.4M | $3.1M | $3.8M | $7.4M | $4.2M | $3.7M | $3.7M | $10.1M | $17.5M |
| Inventory | $3.7M | $2.9M | $2.7M | $2.9M | $2.7M | $2.5M | $2.2M | $3.4M | $2.9M | $2.2M |
| Total assets | $14.0M | $13.7M | $14.7M | $16.2M | $18.8M | $15.0M | $14.6M | $14.4M | $19.2M | $25.5M |
| Total liabilities | $10.9M | $9.3M | $8.6M | $8.3M | $10.1M | $9.6M | $8.9M | $4.0M | $3.9M | $4.0M |
| Shareholders' equity | $3.1M | $4.4M | $6.1M | $8.0M | $8.7M | $5.4M | $5.6M | $7.8M | $15.3M | $21.4M |
Growth · year-over-year · Revenue CAGR 4.8%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +36.7% | +12.2% | -4.0% | +5.1% | -32.2% | +3.9% | -5.5% | +13.9% | +29.9% | +36.9% |
| Net income growth | — | — | — | — | — | — | — | — | -254.5% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.